EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Cytogen Inc (217330) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Cytogen Inc KRW 716, price KRW 3,025, upside -76.3%, quality 30 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7217330000

CI Thin data Sep 24, 2026

Cytogen Inc

217330 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 715.61 KRW · Strongly overvalued (−76%)
!Quality 30/100
!Mixed Growth (revenue 5y +109.7 %/yr)
!Loss-making · -41.7% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (1/8)
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain
Watch Cytogen Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

22,500 KRW 2,320 KRW Fair Value 715.61 KRW Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 2,320 KRW – 22,500 KRW · fair‑value band 472.30 KRW – 894.51 KRW · the 3,025 KRW price screens above the 715.61 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Cytogen in your weekly email

Every Wednesday you see whether Cytogen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea.

Show more

Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is headquartered in Seoul, South Korea.

Stock analysis

Cytogen Inc (217330) currently trades at 3,025 KRW, while our model-based Fair Value estimate is 715.61 KRW, implying the stock looks roughly 322.7% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.

Scenario range: 472.30 KRW (bear) to 894.51 KRW (bull), the price of 3,025 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Cytogen Inc reported revenue of 26.1B KRW in FY2025 versus 348M KRW in FY2021, a compound +194.2%/yr. Reported net income was −12.3B KRW in FY2025.

Key figures

Market cap 69.8B KRW (≈ $51.3M) · P/S ratio 2.52 · Net margin −47.4% · Return on equity −27.7% · Return on assets (EBIT) −20.2% · Operating margin −23.1% · Revenue (TTM) 26.8B KRW · Revenue growth (YoY) +14.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 68% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −76%, 217330 screens richer than that median.

Fair Value models

Bear 472.30 KRW Fair Value 715.61 KRW Bull 894.51 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 768.85 KRW 1,030 KRW 1,538 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 768.85 KRW 1,030 KRW 1,538 KRW 54

Open the full fair value analysis →

Notify me when 217330 reaches fair value

Put 217330 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 30/100

Of which business quality 32 · Market factors (momentum, volatility) 35

Profitability 8
Margins and returns on capital today
Quality Growth 74
Are margins and returns improving?
Cashflow 1
Earnings quality: real cash, not paper profit
Fin. Strength 56
Balance sheet, leverage, solvency risk
Investment 31
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 28
Price trend over the last 3–12 months (market factor)
52W Momentum 30
Distance to the 52-week high (market factor)
Net Issuance 40
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+138.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+224.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+109.7%
Start year 2020 (pandemic). Over 10 years: +48.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+47.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,024.9% (2020) → −28.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

217330 screens 323% overvalued. Compare with Thermo Fisher Scientific Inc →

Compare Cytogen Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −76% · Bottom 25%
Profitability
Return on assets −7% · Bottom 25%
Net margin (TTM) −42% · Bottom 25%
Operating margin (TTM) −23% · Bottom 25%
Growth and dividend
Revenue growth 14% · Above median
Balance sheet
Debt / equity 0.30× · Above median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)70 · sector 25
PAST (return on equity)0 · sector 8
HEALTH (low debt)85 · sector 95
DIVIDEND (yield)0 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $665.30 $682.58 +3%
Danaher Corporation DHR $221.09 $207.76 −6%
WuXi AppTec Co 2359 HK$207.60 HK$228.36 +10%
Lonza Group LONN CHF 570.00 CHF 151.69 −73%
IDEXX Laboratories, Inc IDXX $522.02 $495.84 −5%
Agilent Technologies, Inc A $165.32 $63.90 −61%
Waters Corporation WAT $425.74 $106.31 −75%
IQVIA Holdings IQV $270.09 $295.80 +10%
Illumina, Inc ILMN $255.38 $280.92 +10%
Mettler-Toledo International Inc MTD $1,491 $635.75 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cytogen Inc · Fair Value
715.61 KRW −323%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Cytogen Inc Fair Value". https://www.fairvalue-calculator.com/stock/217330

Frequently asked questions

Is Cytogen Inc (217330) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 715.61 KRW versus a price of 3,025 KRW, about −76% upside (overvalued).
What is the fair value of 217330?
Our model-based fair value for Cytogen Inc is 715.61 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 3,025 KRW.
What is the quality score of 217330?
Cytogen Inc has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cytogen Inc (217330)?
Our model-based price target is the fair value of 715.61 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 472.30 KRW, optimistic scenario 894.51 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Cytogen Inc stock forecast for 2026?
Our models put fair value at 715.61 KRW, about −76% upside versus a price of 3,025 KRW (overvalued). Cautious scenario 472.30 KRW, optimistic scenario 894.51 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Cytogen Inc (217330)?
Cytogen Inc reported trailing-twelve-month revenue of about 26.8B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Cytogen Inc (217330)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cytogen Inc it is 715.61 KRW per share (as of Sep 24, 2026), against a price of 3,025 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Cytogen Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 217330 trades above its calculated fair value: price 3,025 KRW, fair value 715.61 KRW, a gap of about −76% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 217330?
No. The price is what the market pays today (3,025 KRW); the fair value is what the company's own numbers justify (715.61 KRW). For Cytogen Inc the two are 2,309 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Cytogen Inc worth?
The market values Cytogen Inc at about 69.8B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 3,025 KRW; our models calculate a fair value of 715.61 KRW per share.
What do the bullish and bearish scenarios say about 217330?
Our models span a range for Cytogen Inc: cautious scenario 472.30 KRW, base 715.61 KRW, optimistic 894.51 KRW per share (as of Sep 24, 2026, price 3,025 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cytogen Inc (217330)?
Balance-sheet figures for Cytogen Inc (as of Sep 24, 2026): return on equity −27.7%, debt of 0.30 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is 217330 from its 52-week high?
Cytogen Inc trades at 3,025 KRW, about 68% below its 52-week high of 9,420 KRW and 30% above the low of 2,320 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 715.61 KRW is for.
Which stocks are comparable to Cytogen Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cytogen Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 3,025 KRW, calculated fair value 715.61 KRW (−76%), Quality Score 30/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 217330 calculated?
We run Cytogen Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 715.61 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Cytogen Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cytogen Inc (217330)?
The closing price on Sep 23, 2026 was 3,025 KRW. Our model-based fair value is 715.61 KRW, about −76% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cytogen Inc right now?
The price sits above even our optimistic bull case (894.51 KRW). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (472.30 KRW to 894.51 KRW) leaves room in how you read the outcome.

Key figures of Cytogen Inc

How large is the market capitalisation of Cytogen Inc (217330)?
The market capitalisation of Cytogen Inc is 69.8B KRW (≈ $51.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cytogen Inc (217330)?
The price-to-sales ratio of Cytogen Inc is 2.52 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Cytogen Inc (217330)?
The net margin of Cytogen Inc is −47.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cytogen Inc (217330)?
The return on equity (ROE) of Cytogen Inc is −27.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cytogen Inc (217330)?
On an EBIT basis the return on assets of Cytogen Inc is −20.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cytogen Inc (217330)?
The operating margin of Cytogen Inc is −23.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cytogen Inc (217330)?
Revenue at Cytogen Inc is growing +14.0% versus a year earlier (3y avg +225%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cytogen Inc (217330) generate?
The free cash flow of Cytogen Inc is −9.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cytogen Inc (217330) carry?
The net debt of Cytogen Inc is 4.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Cytogen Inc in the live analysis

One click puts Cytogen Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.